Oropharyngeal Cancer Archives - Cancer Therapy Advisor

Racial minorities are poorly represented in genomic research databases, raising important questions

Head and Neck Cancer

African-American Patients Have Worse Outcomes of Oropharyngeal Cancer Regardless of Access to Medical Care

By

Jayme Kunze, PA-C

June 9, 2021

Findings suggest a need for tailored treatment in oropharyngeal squamous cell carcinoma.

Head and Neck Cancer

Study Establishes Feasibility of Reduced-Dose IMRT Plus Cisplatin in Good-Risk HPV-Associated OPSCC

By

Leah Lawrence

February 9, 2021

Investigators tested the efficacy of reduced-dose radiation plus cisplatin in patients with good-risk human papillomavirus–associated oropharyngeal squamous cell carcinoma (OPSCC).

Head and Neck Cancer

Factors Identified for Poor Long-Term Survival in RT-Treated Patients With Oropharyngeal Cancer

By

Susan Moench, PhD, PA-C

January 5, 2021

This analysis identified the factors for poor long-term survival in radiotherapy (RT)-treated patients with oropharyngeal cancer (OPC).

Synchronous metastatic disease is characterized by the presence of metastatic lesions, in addition to the primary tumor, at diagnosis.

Head and Neck Cancer

Transoral Robotic Surgery Ups Survival in Oropharyngeal Cancer

August 25, 2020

Outcomes and survival improved for early-stage oropharyngeal cancer, but not other cancers.

Head and Neck Cancer

Weight and Swallowing-Related Quality of Life in Patients Treated for Oropharyngeal Cancer

By

Vicki Moore, PhD

August 21, 2020

Single-center study reports on the effects of oropharyngeal cancer treatment at 3, 6, and 12 months after chemoradiotherapy or radiotherapy alone, and with and without a feeding tube.

A T-cell therapy that targets a protein only expressed on HPV-positive cancers has shown low toxicity and impressive responses in some patients enrolled in a phase 1/2 clinical trial.

Head and Neck Cancer

Short-Term Mortality Risks Appear Higher in HPV-Negative Oropharyngeal Cancer

By

Leah Lawrence

January 30, 2020

This study assessed causes of early mortality stratified by HPV status in oropharynx cancer.

Head and Neck Cancer

Toxicity Similar, But Overall Survival Poor in Cetuximab vs Cisplatin for HPV-Positive Oropharyngeal Cancer

By

Tiffany Garbutt, PhD

November 26, 2019

In a randomized phase 3 trial, researchers sought to determine if cetuximab-based chemoradiotherapy could be a less-toxic alternative to cisplatin-based chemoradiotherapy in patients with HPV-positive oropharyngeal cancer.

Head and Neck Cancer

Incidence of HPV-Positive OPSCC Is Double That Seen in HPV-Negative Disease

By

Leah Lawrence

August 8, 2019

Incidence was greatest among white men aged 60 to 64 years.

In mice, DNA-encoded plasmids generated sufficient in vivo expression of immune checkpoint antibody

Head and Neck Cancer

Gene Signature Predicts Outcomes in HPV-Related Oropharyngeal Cancers

By

Christina Bennett, MS

February 1, 2019

HPV gene signature was associated with outcomes in patients with HPV-related oropharyngeal cancers and could become a prognostic biomarker.

Oropharyngeal cancers have become the most common HPV-associated malignancies in the US, where the r

Head and Neck Cancer

As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination

By

Bryant Furlow

October 11, 2018

Oropharyngeal cancers have become the most common HPV-associated malignancies in the US, where the rate of vaccination against HPV lags compared with other countries.